Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 14
Review
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 25,834 | Dovepress* | 13,739+ | 2,398 | 16,137 | |
| PubMed Central* | 12,095 | 2,063 | 14,158 | ||
| Totals | 25,834 | 4,461 | 30,295 | ||
| *Since 20 July 2018 | |||||
| Total mentioned | Delicious | Others | |||
|---|---|---|---|---|---|
| 3 | 0 | 0 | 0 | 0 | 3 |
View citations on PubMed Central and Google Scholar